Page last updated: 2024-09-04

pomalidomide and Kidney Diseases

pomalidomide has been researched along with Kidney Diseases in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Biran, N; Duma, N; Richter, J; Siegel, D; Vesole, DH1
Abudayyeh, A; Doshi, M; Edeani, A; Glezerman, IG; Jhaveri, KD; Monga, D; Rosner, M; Wanchoo, R1

Reviews

1 review(s) available for pomalidomide and Kidney Diseases

ArticleYear
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.
    Clinical journal of the American Society of Nephrology : CJASN, 2017, 01-06, Volume: 12, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Everolimus; Humans; Imidazoles; Immunologic Factors; Indoles; Kidney Diseases; Lenalidomide; Multiple Myeloma; Nivolumab; Oligopeptides; Oximes; Proteasome Inhibitors; Protein Kinase Inhibitors; Sulfonamides; Thalidomide; Vemurafenib

2017

Other Studies

1 other study(ies) available for pomalidomide and Kidney Diseases

ArticleYear
Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series.
    Hematological oncology, 2017, Volume: 35, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Humans; Kidney Diseases; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Thalidomide

2017